Beijing Gene Key Life Technology Co., Ltd
Clinical trials sponsored by Beijing Gene Key Life Technology Co., Ltd, explained in plain language.
-
Immune cell infusion aims to free ARDS patients from ventilators
Disease control Not yet recruitingThis study tests an experimental therapy called GKL-006RTU, made from a type of immune cell (iNKT cells), for people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial has two parts: first, a small group receives the c…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase: PHASE1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Immune cell boost plus targeted procedure shows promise for inoperable liver tumors
Disease control Not yet recruitingThis Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the…
Phase: PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC